about
Characterization and distribution of alpha 2-adrenergic receptors in the human intestinal mucosaVPAC receptors: structure, molecular pharmacology and interaction with accessory proteinsIdentification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptideMolecular pharmacology and structure of VPAC Receptors for VIP and PACAPNovel receptor partners and function of receptor activity-modifying proteinsRecurrent PRKAR1A mutation in acrodysostosis with hormone resistanceThe human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20Cloning and functional characterization of the human VIP1/PACAP receptor promoter.The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamicsImpact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice.Purification of a galanin receptor from pig brain.Functional Characterization of PRKAR1A Mutations Reveals a Unique Molecular Mechanism Causing Acrodysostosis but Multiple Mechanisms Causing Carney Complex.The VPAC1 receptor: structure and function of a class B GPCR prototype.Receptors for gut regulatory peptides.Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding.Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology.PTHR1 mutations associated with Ollier disease result in receptor loss of function.Glycosylation of VIP receptors: a molecular basis for receptor heterogeneity.Gs and Gi protein subunits during cell differentiation in intestinal crypt-villus axis: regulation at the mRNA level.Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model.Subtle conformational changes between CX3CR1 genetic variants as revealed by resonance energy transfer assays.Vasoactive intestinal peptide dampens formyl-peptide-induced ROS production and inflammation by targeting a MAPK-p47phox phosphorylation pathway in monocytes.Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge.Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide.A heterotrimeric Gi3-protein controls autophagic sequestration in the human colon cancer cell line HT-29.Interaction of PHM, PHI and 24-glutamine PHI with human VIP receptors from colonic epithelium: comparison with rat intestinal receptors.Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties.The rat liver vasoactive intestinal peptide binding site. Molecular characterization by covalent cross-linking and evidence for differences from the intestinal receptor.Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis.The orexin type 1 receptor is overexpressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis.Biological and structural analysis of truncated analogs of PACAP27.Identification of cytoplasmic domains of hVPAC1 receptor required for activation of adenylyl cyclase. Crucial role of two charged amino acids strictly conserved in class II G protein-coupled receptors.Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP.Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP.The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor.In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma.Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome.Stimulatory effect of pituitary adenylate cyclase-activating polypeptide 6-38, M65 and vasoactive intestinal polypeptide 6-28 on trigeminal sensory neurons.Characterization of the new photoaffinity probe (Bz2-K24)-VIP.
P50
Q24598150-D6A87B5E-2242-44B0-A8FC-804419AFC8A6Q26827172-31993E80-A012-4F61-99E6-5F252485B40FQ28143861-88C11835-FC3E-4566-8E1B-7EB12708DF51Q28200901-506814E9-1266-4147-96FE-6233BE4A0E09Q28215813-6879C293-6D60-4088-9162-E7093375E6DCQ28239792-C1D3A8A7-0BA9-4421-A235-3BF2C4F46E2DQ30859120-FA74ABFC-CA91-4025-865C-5CF2EADFAF5FQ31917596-5C6188B7-A8CC-4116-A249-DDCD014D8EBDQ33643329-50D264A0-9298-4E66-8A0A-3B24AFF58F66Q36248837-6E658A45-D3DD-47E1-9752-0E5575C2A03DQ36267074-4480D1A8-8103-4EBA-8953-CA2A3B406B61Q36282925-32499CF4-B1A7-4D7C-B447-01C8643189D1Q36403782-269CED56-32F7-4EA2-93C7-452EAFD46EB6Q36674242-0450E2CD-78D7-44DC-85EA-A6DEC8589B2EQ36685958-85D38C09-AB5D-4299-8D0C-E9804980F374Q36851462-D5C09B52-F9FD-4A2E-9469-6A221A1FE006Q37294776-C96B2733-543E-4A36-97D4-74061CB80E5FQ38319648-1055AE4C-9E11-4531-869A-7158060DE6BEQ38328474-0BEAA8CC-B488-4962-93A6-40B8686970B3Q38871246-945C52CD-9277-4846-9F6E-F791F3BD9EB2Q39674350-87F98289-7294-41FB-8416-4EDE1C7E7CEDQ39703964-D957F1AD-45B1-476F-B411-7B565D004B0DQ40185725-92486792-C1B1-4376-B014-142878321927Q41197334-BD833E6F-BC86-4E85-860D-0A2CE10B2BD0Q41381644-332FDF72-12B3-4E69-8346-5FCB8E8A1817Q41872532-B614E8D5-B14C-4E89-920F-8872D02863F4Q42554280-A0DE6106-C813-41D0-8C4E-7F3954C7E8A4Q42848909-965448AB-9029-453A-8F01-B61E5004F734Q43297219-5240EF88-2D0A-453E-9A5F-3ECE7AC4EE2DQ43412104-C34E808D-6A86-46BE-828C-5C7FC9A7383AQ43552355-6511E378-D23A-423D-A3E4-08C6CB95BE15Q44400097-19185ADE-06C5-45FD-8401-8998D693A73DQ44674256-0D67807D-CF48-43F8-8C1C-3FAE040BB1B6Q44973271-61D4E6A0-EE24-4835-9FA7-DEE645F334FFQ46494904-9B4CCE51-0CA9-4B9F-9ABD-A256E0BF2AE2Q46505277-5F0628FC-5555-4088-A304-CDE00A4DC29EQ50285016-F8DCB069-BB30-4DDA-9E11-7838E8FA63C1Q51224299-C241499F-495C-4853-93A6-98CEB7C477FCQ51741310-C84B134C-C0D3-492D-BC5E-06910FE5A1EBQ51805255-AF5C950A-5B7B-40B0-9866-03D302CF5204
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alain Couvineau
@ast
Alain Couvineau
@en
Alain Couvineau
@es
Alain Couvineau
@nl
type
label
Alain Couvineau
@ast
Alain Couvineau
@en
Alain Couvineau
@es
Alain Couvineau
@nl
prefLabel
Alain Couvineau
@ast
Alain Couvineau
@en
Alain Couvineau
@es
Alain Couvineau
@nl
P106
P1153
7004155396
P31
P496
0000-0003-2912-5168